fludarabine and isoxazoles

fludarabine has been researched along with isoxazoles in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crowley, J; Eyre, HJ; Hynes, HE; Jaeckle, C; Pollock, TW; Stephens, RL; Taylor, SA1
Dietrich, S; Dreger, P; Giese, T; Hahn, E; Hess, M; Ho, AD; Hüllein, J; Krämer, OH; Luft, T; Rieger, M; Schäfer, C; Tretter, T; Zenz, T1
Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E1
Burnett, AK; Fegan, C; Pearce, L; Pepper, C; Walsby, E1
Best, OG; Mulligan, SP1

Trials

1 trial(s) available for fludarabine and isoxazoles

ArticleYear
Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Evaluation; Female; Glioblastoma; Humans; Isoxazoles; Magnetic Resonance Imaging; Male; Middle Aged; Recurrence; Tomography, X-Ray Computed; Vidarabine

1991

Other Studies

4 other study(ies) available for fludarabine and isoxazoles

ArticleYear
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

    Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Apoptosis; CD40 Ligand; Cell Proliferation; Crotonates; Drug Resistance, Neoplasm; Humans; Hydroxybutyrates; Interleukin-4; Isoxazoles; Janus Kinases; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitriles; Signal Transduction; STAT Transcription Factors; Toluidines; Tumor Cells, Cultured; Vidarabine

2012
The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Atherosclerosis; Cell Line; Cell Separation; gag Gene Products, Human Immunodeficiency Virus; Gene Expression Regulation; GTP-Binding Proteins; HIV Antigens; HIV Infections; HIV-1; Humans; Inflammation; Isoxazoles; Janus Kinases; Lipid Metabolism; Lipopolysaccharide Receptors; Macrophages; Monocytes; Neoplasm Proteins; Neutralization Tests; Phenotype; Phosphorylation; PPAR gamma; Receptors for Activated C Kinase; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones; Vaccination; Vidarabine

2012
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
    Oncotarget, 2012, Volume: 3, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; CASP8 and FADD-Like Apoptosis Regulating Protein; Cells, Cultured; Cytoprotection; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Resorcinols; Signal Transduction; Survivin; Tumor Microenvironment; Vidarabine

2012
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:11

    Topics: Animals; Apoptosis; CD40 Antigens; CD40 Ligand; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunophenotyping; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phenotype; Receptor Tyrosine Kinase-like Orphan Receptors; Resorcinols; STAT3 Transcription Factor; Stromal Cells; Vidarabine

2012